Abstract
Secretory carcinoma (SC) is a recently described salivary gland tumor reported in the fourth edition of World Health Organization classification of head and neck tumors. SC is characterized by strong S-100 protein, mammaglobin, and vimentin immunoexpression, and harbors a t(12;15)(p13;q25) translocation which leads to ETV6-NTRK3 fusion product. Histologically, SC displays a lobulated growth pattern and is often composed of microcystic, tubular, and solid structures with abundant eosinophilic homogenous or bubbly secretion. SC is generally recognized as low-grade malignancy with low-grade histopathologic features, and metastasis is relatively uncommon. In this case, we described a SC of hard palate that underwent high grade transformation and metastasis to the cervical lymph node in a 54-year-old patient. In addition, this case showed different histological findings between primary lesion and metastasis lesion. Therefore, the diagnosis was confirmed by the presence of ETV6 translocation. Here, we report a case that occurred SC with high-grade transformation in the palate, and a review of the relevant literature is also presented.
Highlights
Secretory carcinoma (SC) is a recently recognized malignant tumor arising in the salivary gland.Hirokawa et al pointed out that the histologic and immunochemical features of salivary gland acinar cell carcinoma resembled secretory carcinoma of the breast [1]
The tumor in the metastasis lesion was composed of two contrasting areas (Figure 6a)
Follicle pattern lesion where eosinophilic secretion filled within microcystic space resembled the histology of pattern lesion where eosinophilic secretion within microcystic space resembled the histology of mammary gland secretory carcinoma was filled observed (Figure 6c)
Summary
Kiyofumi Takabatake 1 , Keisuke Nakano 1, * , Hotaka Kawai 1 , Saori Yoshida 1 , Haruka Omori 1 , May Wathone Oo 1 , Shan Qiusheng 1 , Kenichiro Uchida 2 , Katsuaki Mishima 2 and Hitoshi Nagatsuka 1.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
